Group 1 - JD Health reported Q3 2025 revenue of 17.12 billion RMB, a year-on-year increase of 28.7%, and operating profit of 1.243 billion RMB, up 125.3% year-on-year [1] - The company signed strategic cooperation agreements with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, Eisai China, and Bayer China, further establishing its position as the first choice for the online launch of new specialty drugs [1] - JD Health launched various health products, including new generation vitamins and specialized medical foods, achieving their online debut on the platform [1] Group 2 - In September 2025, JD Health partnered with Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital to create a leading smart outpatient service platform [2] - The collaboration aims to implement the "JD Zhuoyi" AI product in outpatient services, establishing a comprehensive AI accompaniment system for patients [2] - Both parties will deepen cooperation in telemedicine, exploring new models of "Internet + healthcare" services [2]